Table 2.
Associations of TNFR1 and TNFR2 slopes, TNFR1 and TNFR2 levels at 0 months, and GFR slope with ESKD in AASK
| Model | Biomarker Slope (per 1 SD increase) | Biomarker Level at t0 (per 1 SD Higher) | GFR Slope (per 1 SD Decrease) | |||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | HR | 95% CI | |
| TNFR1 slope | ||||||
| Unadjusted | 3.61 | 3.05 to 4.26 | — | — | — | — |
| + ln(biomarker) | 3.26 | 2.70 to 3.94 | 2.33 | 1.94 to 2.80 | — | — |
| + age, sex, SBP, BMI, smoking | 3.22 | 2.65 to 3.91 | 2.28 | 1.89 to 2.76 | — | — |
| + GFR, ln(UPCR) | 2.98 | 2.41 to 3.68 | 2.20 | 1.64 to 2.94 | — | — |
| + GFR slope | 2.11 | 1.62 to 2.74 | 1.73 | 1.24 to 2.41 | 2.04 | 1.47 to 2.85 |
| + randomized treatment groups | 2.96 | 2.38 to 3.67 | 2.29 | 1.70 to 3.09 | — | — |
| TNFR2 slope | ||||||
| Unadjusted | 2.52 | 2.21 to 2.87 | — | — | — | — |
| + ln(biomarker) | 2.21 | 1.91 to 2.56 | 2.10 | 1.78 to 2.47 | — | — |
| + age, sex, SBP, BMI, smoking | 2.19 | 1.86 to 2.56 | 2.13 | 1.77 to 2.55 | — | — |
| + GFR, ln(UPCR) | 1.87 | 1.57 to 2.23 | 1.64 | 1.29 to 2.08 | — | — |
| + GFR slope | 1.40 | 1.15 to 1.70 | 1.27 | 0.97 to 1.67 | 2.91 | 2.14 to 3.95 |
| + randomized treatment groups | 1.90 | 1.58 to 2.28 | 1.74 | 1.36 to 2.22 | — | — |
All covariates measured at 0 months except GFR slope, which was measured from 0 to 24 months. n=418 for all models. SD for TNFR1 slope=0.08, TNFR1 at t0=0.37, TNFR2 slope=0.06, TNFR2 at t0=0.40, and GFR slope=3.21. t0=0-month visit; SBP, systolic BP; BMI, body mass index.